Assessment of a Universal Preprocedural Screening Program for COVID-19

dc.contributor.authorDbeibo, Lana
dc.contributor.authorKuebler, Kari
dc.contributor.authorKeen, Alyson
dc.contributor.authorGeorge, Annie
dc.contributor.authorKelley, Kristen
dc.contributor.authorSadowski, Josh
dc.contributor.authorBasham, Laura
dc.contributor.authorBeeson, Terrie
dc.contributor.authorSchmidt, C. Max
dc.contributor.authorBeeler, Cole
dc.contributor.authorWebb, Douglas
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2021-04-15T21:03:42Z
dc.date.available2021-04-15T21:03:42Z
dc.date.issued2021
dc.description.abstractObjectives Study objectives were to: (1) Determine the value of a COVID-19 universal preprocedural screening program; and (2) Using the results of asymptomatic positive screens, determine the safety of resuming elective procedures. Design This was a descriptive study detailing the process and findings from implementation of a COVID-19 universal preprocedural screening program. Setting An adult academic tertiary center in Indiana. Patients Patients were included in the analysis if they were screened 96 hours prior to or within 24 hours after undergoing a procedure in the operating room, cardiac catheterization lab, or endoscopy. Methods A report was generated from the electronic health record of patients undergoing procedures from a six week period of time (May 4th-June 14th, 2020). Health records for positive screens were reviewed and classified as symptomatic if they met either criteria: (1) screen performed due to presence of COVID-19 symptoms; (2) documentation of symptoms at the time of the screen. Patients with a positive screen that did not meet symptomatic criteria were classified as asymptomatic. Descriptive statistics were used to calculate frequencies and percentages for the included sample. Results The initial sample included 2,194 patients, comprised of 46 positive and 2,148 negative screens. Out of the 46 patients who had a positive test, 17 were asymptomatic, resulting in an asymptomatic rate of 0.79% (17/2165). Conclusion Findings validated the value of the program through identification of a low rate of asymptomatic positive screens and procedural team adoption and sustainment. Findings may help inform decision making of like organizations attempting to enhance safety while resuming elective procedures.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationDbeibo, L., Kuebler, K., Keen, A., George, A., Kelley, K., Sadowski, J., ... & Webb, D. (2021). Assessment of a Universal Preprocedural Screening Program for COVID-19. Infection Control & Hospital Epidemiology, 1-9. https://doi.org/10.1017/ice.2021.40en_US
dc.identifier.urihttps://hdl.handle.net/1805/25657
dc.language.isoenen_US
dc.publisherCambridgeen_US
dc.relation.isversionof10.1017/ice.2021.40en_US
dc.relation.journalInfection Control & Hospital Epidemiologyen_US
dc.rightsPublisher Policyen_US
dc.sourceAuthoren_US
dc.subjectCOVID-19en_US
dc.subjectuniversal preprocedural screening programen_US
dc.subjectelective proceduresen_US
dc.titleAssessment of a Universal Preprocedural Screening Program for COVID-19en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Dbeibo2021Assessment.pdf
Size:
158.28 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: